Anti-Inflammatory Peptides Targeting Mediator Release in Uveitis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for uveitis, such as corticosteroids and biologics, are associated with severe side effects, necessitating the development of an effective therapeutic agent that can reduce inflammation without these adverse effects.
Innovation Solution
Administration of peptides with specific amino acid sequences, such as GAQFSKTAAKGEAAAERPGEAAVA (SEQ ID NO. 1) or variants with at least 75% identity, to modulate intracellular signaling and reduce the release of inflammatory mediators in inflammatory cells, using methods like intravitreal injection or topical application.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If corticosteroids are used to treat uveitis, then inflammation is reduced, but severe side effects occur including cataracts, infection, bone loss, and HPA axis suppression
Solution Approach 1:
The patent extracts and targets a specific intracellular signaling pathway (MARCKS protein and its downstream effects on inflammatory mediator release) rather than using broad immunosuppressants. By focusing on this specific molecular mechanism, the therapy achieves anti-inflammatory efficacy without the systemic side effects of traditional corticosteroids and biologics.
Solution Approach 2:
The patent employs peptide sequences with specific amino acid compositions that bind to and modulate the MARCKS protein, changing the functional state of this intracellular signaling component. This molecular-level parameter change enables precise control of inflammatory mediator release without the harmful effects of conventional treatments.
2Reliability
If biologics such as adalimumab are prescribed, then uveitis is treated, but the immune system is weakened leading to increased susceptibility to infections
Solution Approach 1:
The patent extracts and targets a specific intracellular signaling pathway (MARCKS protein and its downstream effects on inflammatory mediator release) rather than using broad immunosuppressants. By focusing on this specific molecular mechanism, the therapy achieves anti-inflammatory efficacy without the systemic side effects of traditional corticosteroids and biologics.
Solution Approach 2:
The peptide therapy exhibits local specificity in its action, targeting the MARCKS protein and its role in inflammatory mediator release within immune cells. This localized molecular target allows the therapy to reduce inflammation at the site of uveitis without broadly suppressing the immune system, thereby avoiding increased infection susceptibility.
3Ease of operation
If atropine is used topically, then pain and spasm of the iris are relieved, but the parasympathetic nervous system is blocked
Solution Approach 1:
The patent replaces the mechanical/neurological approach of atropine (blocking parasympathetic nerves) with a molecular/biochemical approach using peptides that directly modulate intracellular signaling proteins (MARCKS). This substitution achieves similar symptomatic relief through a fundamentally different mechanism that does not block the parasympathetic nervous system.
Data Source
AI summary
The present disclosure includes methods of treating ocular inflammation or inflammatory ocular conditions, such as uveitis. More specifically the present disclosure relates to inhibiting or reducing the release of inflammatory mediators from inflammatory cells by inhibiting the mechanism associated with the release of inflammatory mediators from granules in inflammatory cells. In this regard, the present disclosure includes an intracellular signaling mechanism that illustrates several novel intracellular targets for pharmacological intervention in disorders involving secretion of inflammatory mediators from vesicles in inflammatory cells. Peptide fragments and variants thereof as disclosed in the present disclosure are useful in such methods.